| 产品详情 |
| Edit |   |
|---|
| Product Name | Imatinib, Methanesulfonate Salt (STI-571, CGP-57148B) |
|---|
| Description | HPLC: ≥98%, TLC: ≥98%. A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Imatinib inhibits bcr-abl tyrosine kinase activity, upon which some types of tumor cells depend for growth. Imatinib acts by binding to the ATP binding site of bcr-abl and competitively inhibiting its tyrosine kinase activity. Imatinib is selective for bcr-abl, but it also targets several other kinases (c-kit and PDGF-R). (1) Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. (2) Imatinib inhibits EOL-1 cell viability (IC50 = 0.5 nM), phosphorylation of a fusion protein (IC50 = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC50 = 0.17 nM). (3) Inhibition of CSF-1R by imatinib is competitive with ATP, with a Ki value of 120nM. (4) The IC50 values for imatinib inhi |
|---|
| Size | 25mg, 1g, 5g |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Methanesulfonate; CGP 57148B; Imatinib Mesilate; Imatinib Methanesulfonate; Imatinib Mesylate; STI 571; Bcr-abl Inhibitor IV; Abl Inhibitor V, PDGFR Tyrosine Kinase Inhibitor XXIV, c-Kit Inhibitor IV |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | G2035-20 |
|---|
| Price | |
|---|
| Order / More Info | Imatinib, Methanesulfonate Salt (STI-571, CGP-57148B) from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|